Well done Jenny!!! Many congratulations - very well deserved.
27.11.2025 00:40 — 👍 2 🔁 0 💬 0 📌 0@drrjhewitt.bsky.social
Consultant Respiratory Physician & Interstitial Lung Disease Specialist at Royal Brompton Hospital | Adjunct Senior Lecturer at King’s College London using multi-omics to study early pulmonary fibrosis. https://www.kcl.ac.uk/research/hewitt-lab
Well done Jenny!!! Many congratulations - very well deserved.
27.11.2025 00:40 — 👍 2 🔁 0 💬 0 📌 0
New study on pulmonary fibrosis highlights changes in immune/epithelial cell communication in the lung
publications.ersnet.org/content/erjo...
Thank you Richard @drrjhewitt.bsky.social for allowing me to participate
Thanks Jenny!
23.11.2025 08:50 — 👍 0 🔁 0 💬 0 📌 0
Delighted to share our latest study published in ERJ Open Research.
publications.ersnet.org/content/erjo...
This research provides novel insight into early epithelial and immune aberrations in the airway in IPF and underscores the potential for airway-focused therapeutic approaches in the future.
Last 2 days to apply for this exciting postdoc position investigating early lung fibrosis at @kingscollegelondon.bsky.social - please do consider!
05.08.2025 06:33 — 👍 0 🔁 0 💬 0 📌 0
New postdoc position in my lab investigating interstitial lung abnormalities (ILA) and mechanisms driving early lung fibrosis @kingscollegelondon.bsky.social @rbandh.bsky.social @gstt-nhs.bsky.social @crick.ac.uk
Closing date 7th August.
Please do consider applying!
my.corehr.com/pls/coreport...
Our Review just published in Thorax takes a fresh look at how ageing-associated cellular changes lead to epithelial dysfunction and vulnerability, priming the development of pulmonary fibrosis. @jennydickens41.bsky.social @lpearmain.bsky.social
thorax.bmj.com/content/earl...
Interested in lung epithelial ageing in IPF? Check out our new review - just landed in Thorax @drrjhewitt.bsky.social @lpearmain.bsky.social thorax.bmj.com/content/thor...
28.05.2025 06:20 — 👍 8 🔁 5 💬 0 📌 0Huge congratulations Jenny! Very well-deserved.
24.05.2025 13:55 — 👍 0 🔁 0 💬 0 📌 0A bar chart showing the change from baseline in forced vital capacity at week 52 in the overall trial population
In the FIBRONEER-IPF phase 3 trial, nerandomilast slowed disease progression in patients with idiopathic pulmonary fibrosis as compared with placebo. Full trial results: nej.md/4mgWcIU
#ATS2025 @atscommunity.bsky.social
New postdoc position investigating interstitial lung abnormalities (ILA) and mechanisms driving early lung fibrosis @kingscollegelondon.bsky.social @rbandh.bsky.social @gstt-nhs.bsky.social @crick.ac.uk
Please do consider applying:
www.jobs.ac.uk/job/DLS668/p...
Closing date 18th Feb.
New postdoc position investigating interstitial lung abnormalities (ILA) and mechanisms driving early lung fibrosis @kingscollegelondon.bsky.social @rbandh.bsky.social @gstt-nhs.bsky.social @crick.ac.uk
Please do consider applying:
www.jobs.ac.uk/job/DLS668/p...
Closing date 18th Feb.
We’re conducting a quick, anonymous survey to better understand current practices for managing interstitial lung abnormalities (ILAs) in the UK. Your insights can help improve care pathways and outcomes.
⏱️ Takes just 5 minutes to complete!
👉 tinyurl.com/ytsupxwk
Thanks
I agree!
07.01.2025 19:57 — 👍 0 🔁 0 💬 0 📌 0Thanks Naftali. Please include me! Happy new year!
04.01.2025 23:23 — 👍 0 🔁 0 💬 0 📌 0